(HCM) HUTCHMED DRC - Ratings and Ratios
Fruquintinib, Savolitinib, Surufatinib, Sovleplenib, Tazemetostat
HCM EPS (Earnings per Share)
HCM Revenue
Description: HCM HUTCHMED DRC
HUTCHMED (China) Limited is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapeutics and immunotherapies for cancer and immunological diseases. The company has a diverse pipeline of products, including Fruquintinib, Savolitinib, Surufatinib, Sovleplenib, Tazemetostat, Fanregratinib, and Ranosidenib, targeting various types of cancer such as colorectal, breast, gastric, non-small cell lung, and renal cell carcinoma, among others.
The companys commercialized products and pipeline candidates demonstrate a strong focus on addressing significant unmet medical needs in oncology. Key performance indicators (KPIs) to monitor HUTCHMEDs progress include revenue growth from its commercialized products, particularly Fruquintinib and Savolitinib, as well as the advancement of its pipeline candidates through clinical trials. Other relevant KPIs include the companys R&D expenses as a percentage of revenue, partnerships and collaborations with other pharmaceutical companies, and the companys cash position and burn rate.
HUTCHMEDs collaborations with major pharmaceutical companies such as AstraZeneca, Lilly, Takeda, BeiGene, and Epizyme are also noteworthy, as they provide validation of the companys technologies and potentially significant future milestones and royalties. The companys ability to secure and maintain these partnerships will be an important factor in its future success.
From a financial perspective, HUTCHMEDs market capitalization and P/E ratio suggest that the company is viewed as a growth stock, with investors willing to pay a premium for its potential future earnings. The companys return on equity (RoE) of 5.03% is relatively modest, but this may be expected for a company with significant R&D expenses. Key financial KPIs to monitor include revenue growth, net income, and cash flow from operations.
HCM Stock Overview
| Market Cap in USD | 2,631m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2016-03-17 |
HCM Stock Ratings
| Growth Rating | 8.86% |
| Fundamental | 36.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -10.8% |
| Analyst Rating | 4.43 of 5 |
HCM Dividends
Currently no dividends paidHCM Growth Ratios
| Growth Correlation 3m | 6.2% |
| Growth Correlation 12m | -27.9% |
| Growth Correlation 5y | -49.9% |
| CAGR 5y | 17.18% |
| CAGR/Max DD 3y | 0.38 |
| CAGR/Mean DD 3y | 0.83 |
| Sharpe Ratio 12m | -1.22 |
| Alpha | -12.46 |
| Beta | 0.764 |
| Volatility | 61.70% |
| Current Volume | 47.3k |
| Average Volume 20d | 50.6k |
| Stop Loss | 17 (-3.1%) |
| Signal | -0.37 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (37.7m TTM) > 0 and > 6% of Revenue (6% = 37.8m TTM) |
| FCFTA -0.01 (>2.0%) and ΔFCFTA -15.95pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 109.5% (prev 82.79%; Δ 26.69pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.00 (>3.0%) and CFO 497.0k <= Net Income 37.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (174.6m) change vs 12m ago 2.43% (target <= -2.0% for YES) |
| Gross Margin 10.98% (prev 35.34%; Δ -24.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 49.35% (prev 65.48%; Δ -16.13pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -15.22 (EBITDA TTM -31.4m / Interest Expense TTM 2.87m) >= 6 (WARN >= 3) |
Altman Z'' -0.37
| (A) 0.54 = (Total Current Assets 1.07b - Total Current Liabilities 376.6m) / Total Assets 1.27b |
| (B) -0.65 = Retained Earnings (Balance) -833.2m / Total Assets 1.27b |
| (C) -0.03 = EBIT TTM -43.7m / Avg Total Assets 1.28b |
| (D) -1.49 = Book Value of Equity -746.0m / Total Liabilities 502.3m |
| Total Rating: -0.37 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 36.43
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -0.93% = -0.46 |
| 3. FCF Margin -2.77% = -1.04 |
| 4. Debt/Equity 0.11 = 2.49 |
| 5. Debt/Ebitda -2.73 = -2.50 |
| 6. ROIC - WACC -13.89% = -12.50 |
| 7. RoE 5.03% = 0.42 |
| 8. Rev. Trend 19.29% = 0.96 |
| 9. Rev. CAGR 18.80% = 2.35 |
| 10. EPS Trend 28.02% = 0.70 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of HCM shares?
Over the past week, the price has changed by +8.88%, over one month by +6.63%, over three months by +4.47% and over the past year by +6.11%.
Is HUTCHMED DRC a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HCM is around 14.59 USD . This means that HCM is currently overvalued and has a potential downside of -16.82%.
Is HCM a buy, sell or hold?
- Strong Buy: 9
- Buy: 2
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HCM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.8 | 30.2% |
| Analysts Target Price | 22.8 | 30.2% |
| ValueRay Target Price | 16.3 | -7.2% |
Last update: 2025-09-05 04:45
HCM Fundamental Data Overview
CCE Cash And Equivalents = 836.1m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 5.7623
P/E Forward = 303.0303
P/S = 4.3694
P/B = 2.1443
Beta = 0.589
Revenue TTM = 630.2m USD
EBIT TTM = -43.7m USD
EBITDA TTM = -31.4m USD
Long Term Debt = 59.4m USD (from longTermDebt, last quarter)
Short Term Debt = 26.3m USD (from shortTermDebt, last quarter)
Debt = 85.7m USD (Calculated: Short Term 26.3m + Long Term 59.4m)
Net Debt = -64.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.88b USD (2.63b + Debt 85.7m - CCE 836.1m)
Interest Coverage Ratio = -15.22 (Ebit TTM -43.7m / Interest Expense TTM 2.87m)
FCF Yield = -0.93% (FCF TTM -17.4m / Enterprise Value 1.88b)
FCF Margin = -2.77% (FCF TTM -17.4m / Revenue TTM 630.2m)
Net Margin = 5.99% (Net Income TTM 37.7m / Revenue TTM 630.2m)
Gross Margin = 10.98% ((Revenue TTM 630.2m - Cost of Revenue TTM 561.0m) / Revenue TTM)
Tobins Q-Ratio = -2.52 (set to none) (Enterprise Value 1.88b / Book Value Of Equity -746.0m)
Interest Expense / Debt = 3.35% (Interest Expense 2.87m / Debt 85.7m)
Taxrate = 15.85% (7.19m / 45.4m)
NOPAT = -43.7m (EBIT -43.7m, no tax applied on loss)
Current Ratio = 2.83 (Total Current Assets 1.07b / Total Current Liabilities 376.6m)
Debt / Equity = 0.11 (Debt 85.7m / last Quarter total Stockholder Equity 759.9m)
Debt / EBITDA = -2.73 (Net Debt -64.1m / EBITDA -31.4m)
Debt / FCF = -4.92 (Debt 85.7m / FCF TTM -17.4m)
Total Stockholder Equity = 750.0m (last 4 quarters mean)
RoA = 2.96% (Net Income 37.7m, Total Assets 1.27b )
RoE = 5.03% (Net Income TTM 37.7m / Total Stockholder Equity 750.0m)
RoCE = -5.40% (Ebit -43.7m / (Equity 750.0m + L.T.Debt 59.4m))
RoIC = -5.25% (NOPAT -43.7m / Invested Capital 832.5m)
WACC = 8.64% (E(2.63b)/V(2.72b) * Re(8.83%)) + (D(85.7m)/V(2.72b) * Rd(3.35%) * (1-Tc(0.16)))
Shares Correlation 3-Years: 69.92 | Cagr: 0.25%
Discount Rate = 8.83% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -17.4m)
EPS Correlation: 28.02 | EPS CAGR: 0.0% | SUE: 1.39 | # QB: True
Revenue Correlation: 19.29 | Revenue CAGR: 18.80%
Additional Sources for HCM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle